Lucy A Godley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8097948/publications.pdf

Version: 2024-02-01

161 papers	14,597 citations	53794 45 h-index	19749 117 g-index
166 all docs	166 docs citations	166 times ranked	17475 citing authors

#	Article	IF	Citations
1	Leukemic IDH1 and IDH2 Mutations Result inÂa Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 2010, 18, 553-567.	16.8	2,328
2	Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. Cancer Cell, 2011, 20, 11-24.	16.8	1,105
3	Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nature Biotechnology, 2011, 29, 68-72.	17.5	955
4	Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics, 2012, 44, 23-31.	21.4	916
5	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and IsÂa Recurrent Event during Human Lymphomagenesis. Cancer Cell, 2011, 20, 25-38.	16.8	792
6	5-hmCâ€“mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nature Neuroscience, 2011, 14, 1607-1616.	14.8	746
7	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 2012, 44, 1179-1181.	21.4	692
8	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell, 2015, 27, 658-670.	16.8	341
9	Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nature Genetics, 2015, 47, 180-185.	21.4	299
10	Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature, 2018, 557, 580-584.	27.8	296
11	Large conserved domains of low DNA methylation maintained by Dnmt3a. Nature Genetics, 2014, 46, 17-23.	21.4	276
12	Therapy-Related Myeloid Leukemia. Seminars in Oncology, 2008, 35, 418-429.	2.2	272
13	Therapy-related myeloid neoplasms: when genetics and environment collide. Nature Reviews Cancer, 2017, 17, 513-527.	28.4	270
14	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	6.4	237
15	Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. Journal of Biological Chemistry, 2016, 291, 4256-4265.	3.4	234
16	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica, 2014, 99, 1373-1379.	3.5	213
17	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	1.4	207
18	Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. Cancer Discovery, 2013, 3, 1002-1019.	9.4	180

#	Article	IF	Citations
19	Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood, 2016, 127, 1017-1023.	1.4	179
20	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood, 2011, 118, 2551-2555.	1.4	163
21	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood, 2011, 118, 6438-6445.	1.4	158
22	TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma. Cell Reports, 2014, 7, 1343-1352.	6.4	146
23	Genetic predisposition to hematologic malignancies: management and surveillance. Blood, 2017, 130, 424-432.	1.4	145
24	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapyâ€related leukemia. Cancer, 2016, 122, 304-311.	4.1	129
25	Genome-Wide Variation of Cytosine Modifications Between European and African Populations and the Implications for Complex Traits. Genetics, 2013, 194, 987-996.	2.9	117
26	Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics, 2012, 7, 201-207.	2.7	110
27	ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. Blood Advances, 2019, 3, 2962-2979.	5.2	110
28	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Advances, 2020, 4, 1131-1144.	5.2	102
29	Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Annals of the New York Academy of Sciences, 2014, 1310, 111-118.	3.8	95
30	Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis. Cell Reports, 2014, 6, 231-244.	6.4	93
31	Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia and Lymphoma, 2013, 54, 28-35.	1.3	88
32	DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Reports, 2015, 12, 2086-2098.	6.4	87
33	Inherited Predisposition to Acute Myeloid Leukemia. Seminars in Hematology, 2014, 51, 306-321.	3.4	85
34	Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Advances, 2018, 2, 146-150.	5.2	83
35	TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factorâ€“Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Research, 2015, 75, 2833-2843.	0.9	80
36	5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genetics, 2015, 208, 167-177.	0.4	77

#	Article	IF	Citations
37	Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 417-428.e2.	0.4	74
38	Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Nucleic Acids Research, 2013, 41, e157-e157.	14.5	69
39	Germline ETV6 mutations and predisposition to hematological malignancies. International Journal of Hematology, 2017, 106, 189-195.	1.6	64
40	Genetic predisposition to leukemia and other hematologic malignancies. Seminars in Oncology, 2016, 43, 598-608.	2.2	58
41	DNMT3B7, a Truncated DNMT3B Isoform Expressed in Human Tumors, Disrupts Embryonic Development and Accelerates Lymphomagenesis. Cancer Research, 2010, 70, 5840-5850.	0.9	56
42	Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Research, 2018, 78, 2747-2759.	0.9	56
43	Recognizing familial myeloid leukemia in adults. Therapeutic Advances in Hematology, 2013, 4, 254-269.	2.5	55
44	A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. Journal of Hematology and Oncology, 2018, 11, 4.	17.0	52
45	Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Genome Research, 2017, 27, 1830-1842.	5.5	51
46	TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer. Scientific Reports, 2015, 5, 17568.	3.3	50
47	New themes in the biological functions of 5â€methylcytosine and 5â€hydroxymethylcytosine. Immunological Reviews, 2015, 263, 36-49.	6.0	48
48	Alterations of 5-Hydroxymethylcytosine in Human Cancers. Cancers, 2013, 5, 786-814.	3.7	46
49	Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis. Blood, 2013, 121, 2059-2063.	1.4	44
50	Germline variants drive myelodysplastic syndrome in young adults. Leukemia, 2021, 35, 2439-2444.	7.2	43
51	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2016, 22, 2100-2103.	2.0	42
52	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discovery, 2019, 9, 778-795.	9.4	41
53	The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide. Molecular Cancer Therapeutics, 2014, 13, 1334-1344.	4.1	40
54	Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. Blood, 2016, 127, 310-313.	1.4	39

#	Article	IF	Citations
55	Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Medicine, 2012, 4, 90.	8.2	38
56	Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. Blood, 2016, 127, 1575-1586.	1.4	38
57	The use of hypomethylating agents in the treatment of hematologic malignancies. Leukemia and Lymphoma, 2007, 48, 1676-1695.	1.3	37
58	Recognition of familial myeloid neoplasia in adults. Seminars in Hematology, 2017, 54, 60-68.	3.4	37
59	Linking the genetic architecture of cytosine modifications with human complex traits. Human Molecular Genetics, 2014, 23, 5893-5905.	2.9	36
60	Truncated DNMT3B Isoform DNMT3B7 Suppresses Growth, Induces Differentiation, and Alters DNA Methylation in Human Neuroblastoma. Cancer Research, 2012, 72, 4714-4723.	0.9	35
61	The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nature Communications, 2021, 12, 6468.	12.8	35
62	Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget, 2016, 7, 76816-76826.	1.8	33
63	Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 2021, 35, 3245-3256.	7.2	32
64	A new family with a germlineANKRD26mutation and predisposition to myeloid malignancies. Leukemia and Lymphoma, 2014, 55, 2945-2946.	1.3	30
65	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica, 2016, 101, 634-643.	3.5	30
66	Identification and molecular characterization of a novel 3â€² mutation inRUNX1in a family with familial platelet disorder. Leukemia and Lymphoma, 2010, 51, 1931-1935.	1.3	29
67	The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica, 2021, 106, 3004-3007.	3.5	29
68	Identifying potential germline variants from sequencing hematopoietic malignancies. Blood, 2020, 136, 2498-2506.	1.4	27
69	An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. OncoTargets and Therapy, 2010, 3, 1.	2.0	25
70	Correspondence Regarding the Consensus Statement fromÂtheÂWorldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biology of Blood and Marrow Transplantation, 2016, 22, 183-184.	2.0	24
71	Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology. JCO Precision Oncology, 2021, 5, 107-122.	3.0	24
72	Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Advances, 2020, 4, 4873-4886.	5.2	23

#	Article	IF	Citations
73	Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies. Blood Advances, 2020, 4, 5269-5284.	5.2	23
74	How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for RUNX1 variant curation for germline predisposition to myeloid malignancies. Haematologica, 2020, 105, 870-887.	3.5	23
75	5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. Clinical Cancer Research, 2020, 26, 1309-1317.	7.0	22
76	An Integrated Genomic Approach to the Assessment and Treatment of Acute Myeloid Leukemia. Seminars in Oncology, 2011, 38, 215-224.	2.2	21
77	Gene Mutations, Epigenetic Dysregulation, and Personalized Therapy in Myeloid Neoplasia: Are We There Yet?. Seminars in Oncology, 2011, 38, 196-214.	2.2	21
78	Profiles in Leukemia. New England Journal of Medicine, 2012, 366, 1152-1153.	27.0	21
79	2-Hydroxyglutarate inIDHmutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leukemia and Lymphoma, 2013, 54, 408-410.	1.3	21
80	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML). Leukemia and Lymphoma, 2012, 53, 445-450.	1.3	20
81	Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities. British Journal of Haematology, 2021, 194, 663-676.	2.5	20
82	Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood, 2012, 120, 5247-5249.	1.4	19
83	Germline predisposition to hematopoietic malignancies. Human Molecular Genetics, 2021, 30, R225-R235.	2.9	19
84	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biology of Blood and Marrow Transplantation, 2018, 24, 997-1004.	2.0	18
85	Identifying patients with genetic predisposition to acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2018, 31, 373-378.	1.7	18
86	Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. Current Hematologic Malignancy Reports, 2018, 13, 426-434.	2.3	17
87	Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Genetics in Medicine, 2021, 23, 211-214.	2.4	17
88	Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leukemia and Lymphoma, 2010, 51, 995-1006.	1.3	16
89	Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience. Frontiers in Pediatrics, 2017, 5, 252.	1.9	16
90	Somatic mutation panels: Time to clear their names. Cancer Genetics, 2019, 235-236, 84-92.	0.4	16

#	Article	IF	Citations
91	Identifying potential germline variants from sequencing hematopoietic malignancies. Hematology American Society of Hematology Education Program, 2020, 2020, 219-227.	2.5	16
92	DNMT3B7 Expression Promotes Tumor Progression to a More Aggressive Phenotype in Breast Cancer Cells. PLoS ONE, 2015, 10, e0117310.	2.5	15
93	HIF-1 directly induces TET3 expression to enhance 5-hmC density and induce erythroid gene expression in hypoxia. Blood Advances, 2020, 4, 3053-3062.	5.2	15
94	Breaking the spatial constraint between neighboring zinc fingers: a new germline mutation in GATA2 deficiency syndrome. Leukemia, 2021, 35, 264-268.	7.2	15
95	Germline mutations in MDS/AML predisposition disorders. Current Opinion in Hematology, 2021, 28, 86-93.	2.5	15
96	Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Human Mutation, 2022, 43, 950-962.	2.5	15
97	The Next Frontier for Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2010, 303, 1421.	7.4	14
98	Perturbations of 5-Hydroxymethylcytosine Patterning in Hematologic Malignancies. Seminars in Hematology, 2013, 50, 61-69.	3.4	14
99	5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. JCO Precision Oncology, 2019, 3, 1-12.	3.0	14
100	MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell Chemical Biology, 2020, 27, 538-550.e7.	5.2	14
101	Study of inherited thrombocytopenia resulting from mutations in ETV6 or RUNX1 using a human pluripotent stem cell model. Stem Cell Reports, 2021, 16, 1458-1467.	4.8	14
102	Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies. Current Hematologic Malignancy Reports, 2022, 17, 94-104.	2.3	14
103	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. Blood, 2004, 104, 1145-1145.	1.4	11
104	The identification and characterisation of novelKITtranscripts in aggressive mast cell malignancies and normal CD34+ cells. Leukemia and Lymphoma, 2008, 49, 1567-1577.	1.3	10
105	Characterization of CpG sites that escape methylation on the inactive human X-chromosome. Epigenetics, 2015, 10, 810-818.	2.7	9
106	Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leukemia and Lymphoma, 2016, 57, 1807-1813.	1.3	9
107	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Advances, 2020, 4, 599-606.	5.2	9
108	Genetics of Myelodysplastic Syndromes. Cancers, 2021, 13, 3380.	3.7	9

#	Article	IF	Citations
109	A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias. Genetics in Medicine, 2022, 24, 931-954.	2.4	9
110	The Histone Code and Treatments for Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 960-961.	27.0	8
111	Dnmt3a Is Essential for Hematopoietic Stem Cell Differentiation. Blood, 2011, 118, 386-386.	1.4	7
112	Epigenetic Control of Apolipoprotein E Expression Mediates Gender-Specific Hematopoietic Regulation. Stem Cells, 2015, 33, 3643-3654.	3.2	6
113	Inherited Thrombocytopenia Caused by Germline ANKRD26 Mutation Should Be Considered in Young Patients With Suspected Myelodysplastic Syndrome. Journal of Investigative Medicine High Impact Case Reports, 2020, 8, 232470962093894.	0.6	6
114	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. American Journal of Hematology, 2021, 96, E327-E330.	4.1	6
115	Therapy-Related Myeloid Neoplasms in 109 Patients Following Radiation Monotherapy. Blood Advances, 2021, 5, 4140-4148.	5.2	6
116	Modulators of DNA methylation and histone acetylation. Update on Cancer Therapeutics, 2007, 2, 157-169.	0.4	5
117	HMGA2levels in CML: Reflective of miRNA gene regulation in a hematopoietic tumor?. Leukemia and Lymphoma, 2007, 48, 1898-1899.	1.3	5
118	On the Origin of Leukemic Species. Cell Stem Cell, 2014, 14, 421-422.	11.1	4
119	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2019, 60, 629-638.	1.3	4
120	When should transplant physicians think about familial blood cancers?. Advances in Cell and Gene Therapy, 2019, 2, e68.	0.9	4
121	Regulation of telomeric function by DNA methylation differs between humans and mice. Human Molecular Genetics, 2020, 29, 3197-3210.	2.9	4
122	Efficacy and tolerability of a modified pediatricâ€inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem, 2021, 2, 413-420.	1.0	4
123	Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues. Leukemia and Lymphoma, 2009, 50, 871-872.	1.3	3
124	Preference by Exclusion. Science, 2011, 331, 1017-1018.	12.6	3
125	Regulation of 5-Hydroxymethylcytosine Distribution by the TET Enzymes. RNA Technologies, 2019, , 229-263.	0.3	3
126	Inherited predisposition to myeloid malignancies. Blood Advances, 2019, 3, 2688-2688.	5.2	2

#	Article	IF	Citations
127	Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. Leukemia and Lymphoma, 2020, 61, 246-247.	1.3	2
128	RBL2 bi-allelic truncating variants cause severe motor and cognitive impairment without evidence for abnormalities in DNA methylation or telomeric function. Journal of Human Genetics, 2021, 66, 1101-1112.	2.3	2
129	Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results. Blood, 2020, 136, 41-42.	1.4	2
130	Identical Novel C-Kit Transcripts in Two Patients with Mast Cell Leukemia.. Blood, 2004, 104, 2001-2001.	1.4	2
131	Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations. Blood, 2016, 128, 1212-1212.	1.4	2
132	Assessing the Feasibility and Limitations of Cultured Skin Fibroblasts for Germline Genetic Testing in Hematologic Disorders. Blood, 2020, 136, 35-36.	1.4	2
133	Getting to the root of the stem cell in mutated chronic myeloid leukemia. Leukemia and Lymphoma, 2010, 51, 2147-2148.	1.3	1
134	MBD4: guardian of the epigenetic galaxy. Blood, 2018, 132, 1468-1469.	1.4	1
135	Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.. Blood, 2004, 104, 2321-2321.	1.4	1
136	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. Blood, 2005, 106, 2022-2022.	1.4	1
137	Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. Blood, 2008, 112, 3015-3015.	1.4	1
138	Using sequential next-generation sequencing assays to identify germline cancer predisposition variants.. Journal of Clinical Oncology, 2020, 38, 1581-1581.	1.6	1
139	Limited Effect of TET2 Mutations on Promoter DNA Methylation in Chronic Myelomonocytic Leukemia. Blood, 2011, 118, 1365-1365.	1.4	1
140	Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies. Blood, 2011, 118, 830-830.	1.4	1
141	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discovery, 2019, , .	9.4	0
142	BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines. Haematologica, 2021, 106, 3223-3227.	3.5	0
143	Anticipation in hematopoietic malignancies: biology, bias, or both?. Leukemia and Lymphoma, 2021, 62, 3070-3072.	1.3	0
144	Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.. Blood, 2006, 108, 1952-1952.	1.4	0

#	Article	IF	Citations
145	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 3675-3675.	1.4	0
146	Novel C-KIT Transcripts Identified in Mast Cell Leukemia: An Update of the Full Transcript and Itâ€™s Distribution.. Blood, 2007, 110, 2396-2396.	1.4	0
147	Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study. Blood, 2011, 118, 1948-1948.	1.4	0
148	Myc-Mediated Lymphomagenesis Is Driven by DNA Methylation Changes Induced by DNMT3B7 Expression and Dnmt3b Heterozygosity. Blood, 2011, 118, 225-225.	1.4	0
149	A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. Blood, 2011, 118, 496-496.	1.4	0
150	Dynamic Regulation of 5-Hydroxymethylcytosine At the Î³-Globin Promoter During Erythroid Differentiation. Blood, 2012, 120, 824-824.	1.4	0
151	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. Blood, 2013, 122, 2145-2145.	1.4	0
152	Large Conserved Domains Of Low DNA Methylation Maintained By 5-Hydroxymethycytosine and Dnmt3a. Blood, 2013, 122, 2406-2406.	1.4	0
153	Hematopoietic Stem Cell Function Is Regulated By Hormonal and Epigenetic Factors. Blood, 2013, 122, 1194-1194.	1.4	0
154	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Blood, 2015, 126, 3163-3163.	1.4	0
155	Myeloid Malignancy Variant Curation Expert Panel: An ASH-Sponsored Clingen Expert Panel to Optimize and Validate Acmg/AMP Variant Interpretation Guidelines for Genes Associated with Inherited Myeloid Neoplasms. Blood, 2018, 132, 5849-5849.	1.4	0
156	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood, 2018, 132, 5241-5241.	1.4	0
157	Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 4073-4073.	1.4	0
158	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. Blood, 2019, 134, 3324-3324.	1.4	0
159	Deleterious Germline Variants Are Present in Patients with Myelodysplastic Syndrome of All Ages Treated with Related Allogeneic Stem Cell Transplantation. Blood, 2021, 138, 320-320.	1.4	0
160	Spacing Constraints of Neighboring Zinc Finger Modules within GATA2. Blood, 2021, 138, 3306-3306.	1.4	0
161	Therapy-Related Myeloid Neoplasms in 108 Patients Following Radiation Therapy Only. Blood, 2020, 136, 25-26.	1.4	0